159837 生物科技
午间休市 06-22 11:30:00
资讯
新帖
简况
【新股IPO】广州知易生物科技股份有限公司向港交所主板递交上市申请
金吾财讯 · 06-18
【新股IPO】广州知易生物科技股份有限公司向港交所主板递交上市申请
Parabilis完成6.7亿美元IPO，创风投支持生物科技公司募资纪录
环球市场播报 · 06-11
Parabilis完成6.7亿美元IPO，创风投支持生物科技公司募资纪录
生物科技公司Parabilis上市：市值38亿美元 无收入 年亏1.5亿美元
雷递网 · 06-11
生物科技公司Parabilis上市：市值38亿美元 无收入 年亏1.5亿美元
【新股IPO】真实生物科技向港交所主板递交上市申请书
金吾财讯 · 05-29
【新股IPO】真实生物科技向港交所主板递交上市申请书
大摩：中国生物科技股2026下半年风险回报改善
智通财经网 · 05-29
大摩：中国生物科技股2026下半年风险回报改善
成都迈科康生物科技股份有限公司科创板IPO获受理
每日经济新闻 · 05-27
成都迈科康生物科技股份有限公司科创板IPO获受理
YZi Labs 推出招聘平台 YZi Talent，整合旗下 Web3、AI 和生物科技投资组合职位
链捕手 · 05-25
YZi Labs 推出招聘平台 YZi Talent，整合旗下 Web3、AI 和生物科技投资组合职位
YZi Labs 开放 EASY Residency S4 孵化申请，聚焦 Web3、AI 和生物科技
链捕手 · 05-22
YZi Labs 开放 EASY Residency S4 孵化申请，聚焦 Web3、AI 和生物科技
【ETF动向】5月21日生物科技ETF易方达基金涨0.65%，份额增加1.17亿份
证券之星 · 05-22
【ETF动向】5月21日生物科技ETF易方达基金涨0.65%，份额增加1.17亿份
万联证券：2026Q1公募医药持仓向创新产业链集中 建议关注生物科技公司及大型药企
智通财经 · 05-13
万联证券：2026Q1公募医药持仓向创新产业链集中 建议关注生物科技公司及大型药企
港交所生物科技上市改革成效显著：已有86家公司通过18A上市 市值超1850亿美元
智通财经 · 05-12
港交所生物科技上市改革成效显著：已有86家公司通过18A上市 市值超1850亿美元
李氏大药厂(00950)拟斥资2500万元参投生命健康产业基金 布局生物科技赛道
智通财经 · 05-11
李氏大药厂(00950)拟斥资2500万元参投生命健康产业基金 布局生物科技赛道
12家递表，多家生物科技公司齐招股、上市｜港股IPO周报
21世纪经济报道 · 05-10
12家递表，多家生物科技公司齐招股、上市｜港股IPO周报
大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议
智通财经 · 05-08
大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议
易方达中证生物科技主题ETF发起式联接A基金经理变动：增聘陈英嘉为基金经理
证券之星 · 04-11
易方达中证生物科技主题ETF发起式联接A基金经理变动：增聘陈英嘉为基金经理
圣湘生物（688289）披露关于与关联方共同投资华斯无微生物科技（深圳）有限公司的议案，4月3日股价下跌2.63%
证券之星 · 04-03
圣湘生物（688289）披露关于与关联方共同投资华斯无微生物科技（深圳）有限公司的议案，4月3日股价下跌2.63%
诚益通：公司3月份收到黑龙江伊品生物科技有限公司45万吨氨基酸及配套加工项目淀粉、制糖车间安装工程（ZTAZ-1标）项目中标通知书
证券之星 · 04-01
诚益通：公司3月份收到黑龙江伊品生物科技有限公司45万吨氨基酸及配套加工项目淀粉、制糖车间安装工程（ZTAZ-1标）项目中标通知书
美股异动丨生物科技公司Centessa暴涨近46%，获礼来以高达78亿美元的价格收购
格隆汇 · 03-31
美股异动丨生物科技公司Centessa暴涨近46%，获礼来以高达78亿美元的价格收购
每周股票复盘：安琪酵母（600298）投建白洋生物科技园二期
证券之星 · 03-22
每周股票复盘：安琪酵母（600298）投建白洋生物科技园二期
艾科联生物科技完成数千万美元融资 |【经纬低调新闻】
经纬创投 · 03-19
艾科联生物科技完成数千万美元融资 |【经纬低调新闻】
暂无数据
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159837","market":"SZ","secType":"STK","nameCN":"生物科技","latestPrice":0.419,"timestamp":1782100383000,"preClose":0.427,"halted":0,"volume":47320110,"delay":0,"changeRate":-0.0187,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午间休市","change":-0.008,"latestTime":"06-22 11:30:00","open":0.425,"high":0.425,"low":0.413,"amount":19714600,"amplitude":0.0281,"askPrice":0.419,"askSize":1545,"bidPrice":0.418,"bidSize":60032,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782104400000},"marketStatusCode":3,"adr":0,"adjPreClose":0.427,"symbolType":"fund","openAndCloseTimeList":[[1782091800000,1782099000000],[1782104400000,1782111600000]],"highLimit":0.47,"lowLimit":0.384,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.431971,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159837/tweets","defaultTab":"tweets","newsList":[{"id":"2644408414","title":"【新股IPO】广州知易生物科技股份有限公司向港交所主板递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2644408414","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644408414?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:42","pubTimestamp":1781793770,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所2026年6月18日文件，广州知易生物科技股份有限公司向港交所主板递交上市申请，联席保荐人为兴证国际、国投证券国际。股权架构上，创始人智博士通过持股平台珠海益畅达持有公司 37.26% 股份，为控股股东；多家产业及国资基金为外部主要投资方，上市后实控人仍维持控制权。本次募资将按比例分配：主要投入 SK08 各适应症国内外临床与注册、SK10 全球临床开发，剩余资金用于技术平台迭代、早期管线拓展及补充营运资金。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/YjE3MzU0MjU2ODIzMjIz.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjE3MzU0MjU2ODIzMjIz.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","159837","XBI","BK4581","IPOS","HEXmain","BK4585","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642928261","title":"Parabilis完成6.7亿美元IPO，创风投支持生物科技公司募资纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2642928261","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642928261?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:49","pubTimestamp":1781182140,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Parabilis Medicines本周完成了有史以来规模最大的风投支持生物科技首次公开募股，筹资约6.7亿美元，超出此前由Kailera Therapeutics在今年5月创下的6.25亿美元纪录。 Parabilis成立于2015年，前身为FogPharma，由哈佛大学教授Gregory Verdine创立。 Parabilis此前已通过私募融资筹集超过8亿美元，投资者包括ARCH Venture Partners、Fidelity Investments、RA Capital Management等知名机构。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-iniazyeh5454068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","159837","HBImain","BK4585","BK4581","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642847479","title":"生物科技公司Parabilis上市：市值38亿美元 无收入 年亏1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642847479","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642847479?lang=zh_cn&edition=full","pubTime":"2026-06-11 07:51","pubTimestamp":1781135469,"startTime":"0","endTime":"0","summary":"美国生物科技公司Parabilis Medicines（Nasdaq: PBLS）昨日在美国纳斯达克上市，发行价为20美元，发行3350万股，募资总额为6.7亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260611/6391676106659309226405962.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260611/6391676106659309226405962.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33994/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["XBI","IPOS","BK4581","BK4588","BK4585","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639769926","title":"【新股IPO】真实生物科技向港交所主板递交上市申请书","url":"https://stock-news.laohu8.com/highlight/detail?id=2639769926","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639769926?lang=zh_cn&edition=full","pubTime":"2026-05-29 23:16","pubTimestamp":1780067787,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所5月29日文件，真实生物科技有限公司递交港股主板上市申请，独家保荐人为中金公司。本次募资将主要用于阿兹夫定、CL-197、哆希替尼等核心产品研发商业化，推进各类联合疗法管线开发，搭建药物研发平台，同时补充日常营运资金。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982577","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBImain","IPOS","159837","BK4588","BK4585","BK4581","HEXmain","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639602625","title":"大摩：中国生物科技股2026下半年风险回报改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2639602625","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639602625?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:03","pubTimestamp":1780045429,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大摩发布研报称，中国生物科技股估值已回调至2025年年中水平，而2026财年增长、资金韧性、授权动能及注册型催化剂，均改善了2026下半年的风险/回报。报告指，中国生物科技股2025财年业绩稳健，2026财年指引仍显示创新药收入维持强劲成长，政策持续支持差异化创新，海外授权动能保持强劲。虽然板块仍对利率敏感，但下行风险已逐渐被增长、资金跑道及非稀释性融资所缓冲，而2026下半年将迎来更密集的全球注册型催化剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","XBI","159837","BK4581","BK4585","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507013","title":"成都迈科康生物科技股份有限公司科创板IPO获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507013","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638507013?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:47","pubTimestamp":1779882420,"startTime":"0","endTime":"0","summary":"每经AI快讯，5月27日，据上交所，成都迈科康生物科技股份有限公司科创板IPO获受理，公司拟融资金额29.29亿元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-27/doc-inhzivfi1640541.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-27/doc-inhzivfi1640541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK4581","BK4588","BK4585","HBImain","159837","159982","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638559894","title":"YZi Labs 推出招聘平台 YZi Talent，整合旗下 Web3、AI 和生物科技投资组合职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2638559894","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638559894?lang=zh_cn&edition=full","pubTime":"2026-05-25 23:23","pubTimestamp":1779722638,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，YZi Labs 宣布推出招聘平台 YZi Talent，整合其投资组合中 Web3、AI 及生物科技方向的开放职位。\n\n首批上线职位包括 predict.fun 的后端主任工程师、前端 Staff 工程师，以及 AgriDynamics Robotics 的创始业务负责人，更多公司将陆续加入。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2267135","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","BK4585","159837","HBImain","AIPO","BK4588","CHAT","ARTY","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637397719","title":"YZi Labs 开放 EASY Residency S4 孵化申请，聚焦 Web3、AI 和生物科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2637397719","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637397719?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:03","pubTimestamp":1779440597,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，YZi Labs 宣布启动其旗舰全球孵化项目 EASY Residency 第四季（S4），申请截止时间为 6 月 21 日。此次为期 10 周的创始人项目采用“5 周线上 + 5 周不丹线下”的模式，其线下阶段将在不丹新设立的特殊行政区格莱普正念城进行。入选项目最高可获得 50 万美元投资，包含 15 万美元换取 5% 股权的 SAFE 协议以及 350 万美元无上限的 SAFE 协议，且创始人在不丹期间的住宿、餐饮及工作空间费用全免。\n\n此轮孵化重点关注 Web3、AI 以及生物技术领域，包括全球支付、智能体经济（Agentic Economy）、下一代 DeFi、AI 基础设施、AI × 医疗生物以及 Web3 × 医疗生物等。导师阵容包括赵长鹏、何一及 Balaji 等。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2266587","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","XBI","EASY","159837","AGIX","ARTY","BK4585","AIPO","HBImain","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365440","title":"【ETF动向】5月21日生物科技ETF易方达基金涨0.65%，份额增加1.17亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637365440?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:32","pubTimestamp":1779409936,"startTime":"0","endTime":"0","summary":"证券之星消息，5月21日，生物科技ETF易方达基金（159837）涨0.65%，成交额9934.29万元。当日份额增加了1.17亿份，最新份额为31.22亿份，近20个交易日份额增加2.48亿份。当日资金净流入6376.78万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为14.53亿元。生物科技ETF易方达基金跟踪标的为中证生物科技主题指数，成立（2021-01-14）以来超额回报为2.32%，近一个月超额回报为0.23%，管理人为易方达基金公司，基金经理为张湛 陈英嘉。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200008618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HBImain","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635682278","title":"万联证券：2026Q1公募医药持仓向创新产业链集中 建议关注生物科技公司及大型药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2635682278","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635682278?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:15","pubTimestamp":1778638552,"startTime":"0","endTime":"0","summary":"万联证券主要观点如下：截至2026Q1，医药主题基金规模环比增加59.90亿元医药生物占所有行业重仓总市值的百分比环比增加0.90个百分点，生物制品和医疗服务重仓总市值环比增加较多，公募基金医药持仓结构继续向创新药及CXO等创新产业链集中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159837","BK4588","BK1161","BK1574","HBImain","159938","BK1515","161027","BK4581","XBI","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213441","title":"港交所生物科技上市改革成效显著：已有86家公司通过18A上市 市值超1850亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213441","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634213441?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:13","pubTimestamp":1778584387,"startTime":"0","endTime":"0","summary":"新规生效以来，已有86家生物科技公司透过该制度上市，集资总额超过178亿美元。截至2026年4月16日，这些公司市值合计超过1850亿美元。截至2026年4月，在香港交易所上市的生物科技及医疗保健相关公司已超过276家，合计市值逾5万亿港元。按NextPharma数据，2025年涉及中国创新药对外授权交易总值达1,360亿美元。随着投资者对生物科技ETF的兴趣显著升温，香港上市生物科技ETF的资产管理规模，已由2021年3月的15亿港元，大幅增至2026年3月底的120亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","XBI","HBImain","159837","BK4581","HEXmain","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634280989","title":"李氏大药厂(00950)拟斥资2500万元参投生命健康产业基金 布局生物科技赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2634280989","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634280989?lang=zh_cn&edition=full","pubTime":"2026-05-11 22:26","pubTimestamp":1778509575,"startTime":"0","endTime":"0","summary":"李氏大药厂(00950)公布，于2026年5月11日，公司的间接全资附属公司兆科合肥、普通合伙人瑞伏博健及其他有限合伙人订立有限合伙协议，据此，该等合伙人向基金出资人民币2亿元，而兆科合肥同意向基金出资人民币2500万元，相当于约12.5%基金权益。基金的目的为寻求投资于生命与健康、生物科技及相关上下游行业的非上市实体，符合公司的业务策略，透过于医药领域的策略合伙、投资及收购加强业务。投资基金符合集团的核心策略，透过具影响力的合伙及收购扩大其医药及保健版图。借认购基金的有限合伙权益，该集团得以间接涉足生物科技及生命科学领域的非上市实体的高增长，善用普通合伙人深厚的行业知识。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK4585","BK1587","159837","HBImain","BK1583","06622","BK1574","XBI","BK4588","00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634844328","title":"12家递表，多家生物科技公司齐招股、上市｜港股IPO周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2634844328","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634844328?lang=zh_cn&edition=full","pubTime":"2026-05-10 09:59","pubTimestamp":1778378340,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 吴歌Wind数据显示，5月4日—5月10日，当周有12家公司向港交所递表，2家公司通过聆讯，3家公司持续招股，2家公司成功挂牌上市。此外，还有天星医疗、可孚医疗两只医疗领域新股纷纷上市。本周共有12家公司向港交所递表：5月4日，江西生物向港交所主板提交上市申请，中金公司及招商证券国际担任联席保荐人。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-10/doc-inhxkper7882466.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-10/doc-inhxkper7882466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","VXUS","BK4581","BK4588","BK4585","HBImain","159837","XBI","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633391434","title":"大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2633391434","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633391434?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:26","pubTimestamp":1778232395,"startTime":"0","endTime":"0","summary":"智通财经APP讯，大成生化科技 发布公告，本公司间接全资附属公司长春大成大合生物技术开发有限公司与神舟生物科技有限责任公司订立合作协议，据此，神舟生物科技同意委聘大成大合生产辅酶Q10菌丝体。双方亦协定，在神舟生物科技对产品检验合格后，神舟生物科技将根据其月度采购计划向大成大合采购辅酶Q10菌丝体，于2027年1月1日至2028年12月31日期间的最低采购量为1270公吨辅酶Q10。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159837","HBImain","BK4585","BK4581","BK4588","00809","XBI","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626155141","title":"易方达中证生物科技主题ETF发起式联接A基金经理变动：增聘陈英嘉为基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2626155141","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626155141?lang=zh_cn&edition=full","pubTime":"2026-04-11 09:31","pubTimestamp":1775871119,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月11日，易方达中证生物科技主题ETF联接发起式发布公告，增聘陈英嘉为基金经理，任职日期自2026年4月11日起，李栩不再担任该基金基金经理，离任日期为2026年4月11日，变更后易方达中证生物科技主题ETF联接发起式的基金经理为陈英嘉。截止2026年4月10日，易方达中证生物科技主题ETF联接发起式净值为0.9457，较上一日上涨0.8%，近一年上涨11.19%。2026年3月5日起任易方达中证生物科技主题交易型开放式指数证券投资基金基金经理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041100006188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591736","title":"圣湘生物（688289）披露关于与关联方共同投资华斯无微生物科技（深圳）有限公司的议案，4月3日股价下跌2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624591736?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:40","pubTimestamp":1775209229,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，圣湘生物报收于17.76元，较前一交易日下跌2.63%，最新总市值为102.9亿元。该股当日开盘18.19元，最高18.22元，最低17.75元，成交额达7054.79万元，换手率为0.68%。公告显示，公司于2026年3月31日召开2026年第一次临时股东会，审议通过《关于与关联方共同投资华斯无微生物科技（深圳）有限公司的议案》。关联股东未出席本次会议。湖南启元律师事务所对本次会议进行了见证并出具法律意见书，认为会议决议合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HBImain","688289","BK0239","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624560898","title":"诚益通：公司3月份收到黑龙江伊品生物科技有限公司45万吨氨基酸及配套加工项目淀粉、制糖车间安装工程（ZTAZ-1标）项目中标通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624560898","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624560898?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:00","pubTimestamp":1775026842,"startTime":"0","endTime":"0","summary":"证券之星消息，诚益通03月31日在投资者关系平台上答复投资者关心的问题。诚益通回复：尊敬的投资者您好，公司3月份收到黑龙江伊品生物科技有限公司45万吨氨基酸及配套加工项目淀粉、制糖车间安装工程项目中标通知书，中标金额为1775.57万元，目前暂未签订合同，签订合同日期以实际签约时间为准。该项目金额未达到重大合同披露标准。如达到信息披露标准，公司将按法律法规要求进行披露，请您关注公司公告。再次感谢您的建议和支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100021937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0225","159837","BK0130","300430","BK0028","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623071538","title":"美股异动丨生物科技公司Centessa暴涨近46%，获礼来以高达78亿美元的价格收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2623071538","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623071538?lang=zh_cn&edition=full","pubTime":"2026-03-31 23:09","pubTimestamp":1774969770,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"044b49fac9463464d2e44ed274e1a9ed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4599","LU0266013472.USD","LU2111349929.HKD","SG9999015952.SGD","LU0787776722.HKD","LU2471134952.CNY","LU0889565916.HKD","IE00B7KXQ091.USD","LU1069344957.HKD","BK4534","SGXZ99366536.SGD","LU2361044949.HKD","LU0820561818.USD","LU1623119135.USD","LLYZ","LLY","LU0354030511.USD","LLYX","LU0158827948.USD","159837","IE00BJJMRX11.SGD","LU1280957306.USD","ELIL","LU0353189680.USD","XBI","LU2361044865.SGD","LU0316494557.USD","LU2756315664.SGD","SG9999013999.USD","LU2271345857.HKD","LU0786609619.USD","LU1989771016.USD","LU0353189763.USD","LU2023250330.USD","LU2023250504.SGD","HBImain","LU2168564149.EUR","LU2602419157.SGD","LU0823434583.USD","LU1974910355.USD","LU0471298694.HKD","LU1023059063.AUD","LU0079474960.USD","LU0820562030.AUD","BK4533","ELIS","LLII","LU1804176565.USD","LU1093756325.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621796084","title":"每周股票复盘：安琪酵母（600298）投建白洋生物科技园二期","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796084","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796084?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:26","pubTimestamp":1774117573,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，安琪酵母报收于40.17元，较上周的42.09元下跌4.56%。本周，安琪酵母3月16日盘中最高价报42.3元。本周关注点公司公告汇总：安琪酵母拟投资79,739万元实施白洋生物科技园项目二期。公司公告汇总安琪酵母股份有限公司于2026年3月18日召开第十届董事会第十一次会议，审议通过多项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","159837","HBImain","LU2148510915.USD","BK0226","BK0175","LU2580892789.USD","BK0185","LU1064130708.USD","LU1064131003.USD","LU2580892862.HKD","600298","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620733247","title":"艾科联生物科技完成数千万美元融资 |【经纬低调新闻】","url":"https://stock-news.laohu8.com/highlight/detail?id=2620733247","media":"经纬创投","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620733247?lang=zh_cn&edition=full","pubTime":"2026-03-19 12:06","pubTimestamp":1773893160,"startTime":"0","endTime":"0","summary":"综述今日，专注于研发肿瘤与自身免疫性疾病下一代 T 细胞衔接器疗法的生物技术企业艾科联生物科技 宣布，公司已顺利完成超额认购的 6870 万美元融资。艾科联生物科技由方磊博士与朱杰伦先生联合创立。艾科联生物科技首创“中国式 NewCo”模式，整合连续创业家团队、优质管线资产与顶尖资本各核心要素，加速药物研发进程。目前，公司已迅速成长为一家聚焦下一代 TCE 疗法的多平台临床阶段的生物技术企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962187047&idx=2&sn=0355725ff34196e2d12bba68f7a9ce9c&chksm=ab6e3f36652f88018e812be9e1f5cf2932a3592d9796294fd50ce1d539e376eb04fae7ba78e5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4588","BK4581","XBI","BK4585","159837"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782100402339,"stockEarnings":[{"period":"1week","weight":0.0289},{"period":"1month","weight":-0.0797},{"period":"3month","weight":-0.0837},{"period":"6month","weight":-0.1528},{"period":"1year","weight":-0.0837},{"period":"ytd","weight":-0.1356}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,159837,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}